Vocera announces first clinical communications app for Apple Watch

SAN JOSE, Calif., April 13, 2015 -- Vocera Communications, Inc. (NYSE:VCRA), the leading provider of real-time, intelligent communication solutions for mission-critical healthcare environments, today announced the Vocera app for Apple Watch. The Apple Watch enables Vocera to extend the power of the Vocera Communication Platform in new ways so physicians and care teams can engage with and respond to life-critical communications and alerts.

The Vocera app for Apple Watch will allow users to rapidly manage life-critical communications by viewing and responding to prioritized calls, alerts, and messages from other care team members, Electronic Health Records (EHR) and clinical systems, including critical lab values and STAT orders. In addition, users will be able to manage key communication functions by setting their availability to enable proper message routing. The Vocera app also allows users to initiate panic calls in "man-down" emergency situations, improving staff safety.

"Our core mission is to provide secure, integrated solutions that are easy to use and improve care team collaboration," said Brent Lang, president and CEO of Vocera. "The Apple Watch offers a revolutionary new way for us to efficiently deliver critical information to the right person, at the right time, in the right place."

"The Vocera app uses the Apple Watch Actionable Notification feature to deliver vital information directly to a user's wrist and leverages Watch Glances to speed time to response," said Gautam M. Shah, vice president of product management at Vocera. "We're excited to leverage Apple Watch to enhance the value and functionality of the Vocera Communication Platform."

This announcement comes on the heels of several new solutions from Vocera designed to address care coordination, including a HIPAA-compliant secure texting solution, and enhanced functionality enabling interactive communications with EHR systems.

The Vocera app will be available this summer from the Apple Watch App Store and can be previewed this week at the company's booth (#2012) at the 2015 HIMSS conference in Chicago. Other Vocera apps for iPhone are currently available and can be downloaded from the App Store. Please visit www.vocera.com/watch for more information.

About Vocera

Vocera Communications, Inc. (NYSE:VCRA) empowers teams through intelligent, real-time communication and collaboration in healthcare, hospitality, energy, and other mission-critical mobile environments.

Widely recognized for developing smarter ways to communicate, Vocera offers enterprise-class technologies that enable collaboration for mobile teams on their device of choice. Vocera solutions are installed in more than 1,200 organizations worldwide, improving efficiency, quality, safety and outcomes while creating optimal working and healing environments. Via the company's research collaborative, the Experience Innovation Network, Vocera also drives thought leadership for the healthcare industry and new standards in care delivery to elevate patient, family, nurse and physician experiences. Vocera is headquartered in San Jose, California, with offices in San Francisco, Tennessee, Canada, India, United Arab Emirates, and the United Kingdom.

For more information, visit www.vocera.com and @VoceraComm on Twitter.

The Vocera logo is a trademark of Vocera Communications, Inc. Vocera(R) is a trademark of Vocera Communications, Inc. registered in the United States and other jurisdictions. All other trademarks appearing in this release are the property of their respective owners.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.